Clinical Trial Update: Nebulized Heparin for Prevention of Acute Lung Injury in Smoke Inhalation Injury [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating nebulized heparin for prevention of acute lung injury in smoke inhalation injury has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Injury
• Smoke Inhalation Injury

Drugs mentioned

• Nebulized Heparin (unfractionated heparin)

Snippet

Sponsor: Ain Shams University | Conditions: Smoke Inhalation Injury, Acute Lung Injury | Phase 3 | Status: COMPLETED